Compile Data Set for Download or QSAR
Report error Found 33 Enz. Inhib. hit(s) with all data for entry = 50041394
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166695(3-(5-Methoxy-pyridin-3-yl)-3-{5-[2-(5,6,7,8-tetrah...)
Affinity DataIC50: 0.25nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166693(3-Pyridin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]na...)
Affinity DataIC50: 0.25nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166677(3-(5-Cyano-pyridin-3-yl)-3-{5-[2-(5,6,7,8-tetrahyd...)
Affinity DataIC50: 0.260nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166688(3-(6-Methanesulfonyl-pyridin-3-yl)-3-{5-[2-(5,6,7,...)
Affinity DataIC50: 0.300nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166683(3-Quinolin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]n...)
Affinity DataIC50: 0.380nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166678(3-Benzo[1,3]dioxol-5-yl-3-{5-[2-(5,6,7,8-tetrahydr...)
Affinity DataIC50: 0.380nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166669(3-(5-Methanesulfonyl-pyridin-3-yl)-3-{5-[2-(5,6,7,...)
Affinity DataIC50: 0.460nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166675(3-(3-Chloro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1...)
Affinity DataIC50: 0.5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166668(3-(4-Fluoro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1...)
Affinity DataIC50: 0.700nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166680(3-(4-Methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[...)
Affinity DataIC50: 0.700nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166682(3-(3-Methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[...)
Affinity DataIC50: 0.800nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166665(3-Pyridin-4-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]na...)
Affinity DataIC50: 0.900nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166691(3-phenyl-3-(5-(2-(5,6,7,8-tetrahydro-1,8-naphthyri...)
Affinity DataIC50: 1nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166692(3-(2-Methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[...)
Affinity DataIC50: 1.10nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166673(3-Pyridin-2-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]na...)
Affinity DataIC50: 1.20nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166674(3-{5-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl...)
Affinity DataIC50: 5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166672(3-{5-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl...)
Affinity DataIC50: 6nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166687(3-Benzo[1,3]dioxol-5-yl-3-{5-[2-(3,4-dihydro-2H-py...)
Affinity DataIC50: 8nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166679(3-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl...)
Affinity DataIC50: 23nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50161783(3-{5-[2-(6-Methylamino-pyridin-2-yl)-ethoxy]-indol...)
Affinity DataIC50: 36nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166686(3-Naphthalen-1-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8...)
Affinity DataIC50: 37nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166666(3-Naphthalen-2-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8...)
Affinity DataIC50: 37nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166685(3-Biphenyl-4-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]n...)
Affinity DataIC50: 40nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166690(3-(2-Chloro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1...)
Affinity DataIC50: 55nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166671(3-{5-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl...)
Affinity DataIC50: 78nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166676(3-{5-[2,2-Difluoro-2-(5,6,7,8-tetrahydro-[1,8]naph...)
Affinity DataIC50: 130nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166681(3-(5-{2-[N-(4,5-Dihydro-1H-imidazol-2-yl)-aminooxy...)
Affinity DataIC50: 200nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166684(2-Methyl-3-{5-[3-(pyridin-2-ylamino)-propoxy]-indo...)
Affinity DataIC50: 460nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50161784(3-{5-[3-(Pyridin-2-ylamino)-propoxy]-indol-1-yl}-p...)
Affinity DataIC50: 470nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166689(2-Benzyl-3-{5-[3-(pyridin-2-ylamino)-propoxy]-indo...)
Affinity DataIC50: 1.90E+3nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166670(2-{5-[3-(Pyridin-2-ylamino)-propoxy]-indol-1-ylmet...)
Affinity DataIC50: 2.00E+3nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166694(4-{5-[3-(Pyridin-2-ylamino)-propoxy]-indol-1-yl}-b...)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50166667(2-{5-[3-(Pyridin-2-ylamino)-propoxy]-indol-1-yl}-b...)
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed